Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

I-Mab Inks Deal To Divest Its Assets And Business Operations In China

Author: Benzinga Newsdesk | February 07, 2024 07:40am

The Company will transfer 100% of the outstanding equity interest in I-Mab Biopharma Co., Ltd., a wholly owned subsidiary of the Company that operates the Company's business in China, on a cash-free and debt-free basis, to the Hangzhou Company for an aggregate consideration of the RMB equivalent of up to $80 million, contingent on the Hangzhou Company group's achievement of certain future regulatory and sales-based milestone events. 

Posted In: IMAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist